Posted by Michael Wonder on 19 Dec 2021
FDA approves Telix’s prostate cancer imaging product, Illuccix
19 December 2021 - Telix Pharmaceuticals today announces that the United States FDA has approved Telix’s lead prostate cancer imaging product, Illuccix.
With a distribution network encompassing more than 140 nuclear pharmacies through its agreements with Cardinal Health and PharmaLogic, Telix will be able to provide Illuccix to more than 85% of eligible PET imaging sites throughout the United States.
